Dun & Bradstreet, the world’s leading provider of business information, knowledge and insight launched its first edition of India’s Leading Pharmaceutical Companies. The 2016 edition of the publication profiles 134 leading pharmaceutical companies in India. The publication highlights the significance of the Indian pharmaceuticals sector and its contribution to the Indian economy. It also endeavors to showcase the Indian pharmaceutical sector’s position in the global context. The significance of India’s pharmaceuticals sector can be gauged from the fact that in FY16, India’s exports of pharmaceutical products stood at USD 16.9 bn, which was about 5% of the aggregate value of India’s total exports during the year.
On the occasion of the launch of the publication, a knowledge forum was also held. The forum focused at acknowledging the valuable role of the leading players of pharmaceutical industry as well as offering a platform to discuss the industry’s critical areas for realizing its true potential. It was addressed by eminent industry leaders and policymakers including Shri Faggan Singh Kulaste, Hon. Minister of State for Health & Family Welfare and Shri Sudhansh Pant, IAS, Joint Secretary, Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers.
The 2016 edition of the ‘India’s Leading Pharmaceutical Companies’ publication profiles 134 companies in the Indian pharmaceuticals sector, with a total income of at least Rs 1,000 mn as per their latest financial statements (FY16 or FY15) and who have reported profits at the net level either at the standalone or the consolidated level. Of the 134 companies being profiled in the publication, financial data for FY16 was available for around 59 companies.
Key highlights of India’s Leading Pharmaceutical Companies based on FY15 and FY16 financial performance are:
· The aggregate value of India’s pharmaceuticals exports stood at USD 16.9 bn in FY16, which was 9.4% higher than the USD 15.4 bn exported in the preceding year
· The North American region accounted for more than one-thirds of India’s pharmaceutical exports in FY16, followed by Africa (~20%) and the European Union (~15%)
· A whopping 55% of India’s pharmaceutical exports are to highly regulated markets like the USA and UK
Key highlights for 59 companies based on FY16 financial performance are:
· The aggregate total income grew by a healthy 11.5% as compared to a year ago - this is attributed to growing demand for pharmaceutical products, both within India and abroad
· The aggregate value of export of goods reflected a 17% growth in FY16, which is much faster than the 9.4% growth in India’s overall pharmaceutical exports during the year
· The aggregate net profit rose by a sharp 41.3% as compared to FY15 – this growth is attributed to the robust growth in exports, which are profitable for the sector, and a much slower rise in the sector’s largest expense head, ‘raw material expenses’
· In FY16, raw material expenses rose by merely 3.1%; the prices of bulk chemicals, which are used as starting materials for most companies in the sector, have remained low due to cheap imports from China and Indian suppliers of APIs being forced to keep their prices low
· The R&D spending rose by a robust 23.5% as compared to FY15; R&D spending as a percentage of total income expanded from 5.6% in FY15 to 6.2% in FY16, reflecting the increasing focus on R&D activity and innovation
Delivering the welcome address Mr. Kaushal Sampat, President & Managing Director - India, Dun & Bradstreet said, “India’s pharmaceutical market size stands at around Rs.1.7 trillion. Pharmaceutical exports stand at around US$ 17 bn, and it contributes to about 20% of the global exports in generics. India is also among the major exporters of Active Pharmaceutical Ingredients (APIs)/bulk drugs. Today, India is making a huge difference in providing affordable healthcare and in developing cures and treatments for life-threatening diseases like cancer, cardiovascular diseases, diabetes and other lifestyle diseases, among others. This is a testament to the global leadership that the Indian pharmaceuticals industry has achieved”.
“The Indian pharmaceuticals sector is playing a delicate balancing act, trying their best to stay profitable while not compromising on R&D and innovation. Many of the pharmaceutical companies are willing to take a hit on their profits to pursue R&D and come up with new cures, new treatments and new innovations No doubt, manufacturing of pharmaceuticals is a serious business, but it is commendable that Indian pharmaceutical companies are focusing on making their products not only effective, but also affordable for the masses”, Kaushal further added.
The launch also witnessed a panel discussion titled “Making India a Hub for Pharma Manufacturing and R&D”, addressed by key leaders from the sector. The forum was well attended by the industry representatives, setting the tone for the future editions of the report in the coming years.
About Dun & Bradstreet (D&B)
Dun & Bradstreet (NYSE: DNB) grows the most valuable relationships in business. By uncovering truth and meaning from data, we connect customers with the prospects, suppliers, clients and partners that matter most, and have since 1841. Nearly ninety percent of the Fortune 500 and companies of every size around the world, rely on our data, insights and analytics.
Customers use D&B Risk Management Solutions to mitigate risk, increase cash flow and drive increased profitability; D&B Sales & Marketing Solutions to manage their master data, analyse markets, locate prospects and increase revenue from new and existing customers; D&B Economic Analysis Group for solution-oriented analyses of strategic economic and business developments, thereby aiding informed decision making and D&B Learning Solutions to facilitate professional growth and excellence among their executives.
In 2016, D&B featured on the World’s Most Ethical Companies list in the Business Services category by Ethisphere, for the eighth consecutive year. The World’s Most Ethical Companies designation recognizes companies that truly go beyond making statements about doing business “ethically” and translates those words into action.
For more information, please visit www.dnb.co.in
Contact us